Foram Parekh

Could you please disclose or highlight on the peptide capacity, the dedicated peptide capacity? And what would be the capex allotted for the peptides?

Okay. And would you be comfortable disclosing the capex dedicated towards the peptide program?

Okay, My second question is on the CDMO side. In the previous con calls, you had alluded that you envisaged CDMO contribution going towards 50% of the total sales. So as per your internal assessment and now that the CDMO pie is growing well and we have strong order books, so how soon do you see, as per the internal assessment, 50% number being achievable?

Could you please disclose or highlight on the peptide capacity, the dedicated peptide capacity? And what would be the capex allotted for the peptides?

Okay. And would you be comfortable disclosing the capex dedicated towards the peptide program?

Okay, My second question is on the CDMO side. In the previous con calls, you had alluded that you envisaged CDMO contribution going towards 50% of the total sales. So as per your internal assessment and now that the CDMO pie is growing well and we have strong order books, so how soon do you see, as per the internal assessment, 50% number being achievable?

Thank you for the opportunity, and congrats on a good set of numbers. My first question is on the domestic side. We mentioned that our in-licensed portfolio is 6% to 7% of the total sales and probably low to mid-double-digit contribution of the domestic sales. So, my question is, do we have any threshold limit that beyond this, the in-licensing portfolio should not exceed.

Yes. But can you comment on the gross margin percentage? I mean, something that beyond which we feel that it will not slip? Is there some percentage do we have or we can guide upon?

Sure. And my second question is on the European side. We believe that Amphotericin B has been launched in Italy and fully present in UK. So if you can just guide us how many count ries are we still expecting the launch to be in Europe? And therefore, this quarter's growth rate, would it be able to measure in the subsequent quarters as well?